MJP Associates Inc. ADV Has $233,000 Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

MJP Associates Inc. ADV decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 72.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,263 shares of the medical research company's stock after selling 3,334 shares during the quarter. MJP Associates Inc. ADV's holdings in Charles River Laboratories International were worth $233,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in CRL. Pinnacle Bancorp Inc. grew its position in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after purchasing an additional 65 shares in the last quarter. Optiver Holding B.V. purchased a new position in shares of Charles River Laboratories International during the 4th quarter valued at $37,000. GeoWealth Management LLC grew its holdings in shares of Charles River Laboratories International by 311.5% during the 4th quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after acquiring an additional 190 shares in the last quarter. Pilgrim Partners Asia Pte Ltd purchased a new position in shares of Charles River Laboratories International during the 4th quarter valued at $48,000. Finally, Tortoise Investment Management LLC grew its holdings in shares of Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after acquiring an additional 115 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Insiders Place Their Bets

In related news, CEO James C. Foster acquired 6,075 shares of the company's stock in a transaction dated Thursday, February 20th. The shares were bought at an average price of $165.01 per share, for a total transaction of $1,002,435.75. Following the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. This trade represents a 3.42% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the business's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares in the company, valued at approximately $3,252,112.50. The trade was a 18.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,040 shares of company stock valued at $807,407 in the last quarter. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock traded up $2.11 on Friday, reaching $141.00. 1,473,414 shares of the stock were exchanged, compared to its average volume of 982,521. The stock has a market cap of $6.93 billion, a PE ratio of 940.00, a PEG ratio of 4.54 and a beta of 1.50. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $254.15. The firm has a fifty day moving average price of $135.94 and a two-hundred day moving average price of $165.27.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. The firm had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business's revenue was down 2.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.27 EPS. Sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday. Robert W. Baird boosted their price target on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a report on Thursday, May 8th. The Goldman Sachs Group cut shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their price target for the company from $190.00 to $170.00 in a report on Friday, March 21st. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price target on the stock in a report on Monday, March 3rd. Finally, JPMorgan Chase & Co. lowered their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $172.31.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).